Skip to main content

Table 1 qRT-PCR analysis of Wnt ligands and FZD receptor expression in primary MCL cells compared to B-cells from healthy donors

From: Targeting Wnt pathway in mantle cell lymphoma-initiating cells

  MCL-non-ICs MCL-ICs P value
Median 95 % CI Median 95 % CI
Wnt Ligands  
 Up-regulated in MCL-non-ICs and MCL-ICs  
  Wnt3a 17.555 0.12–56.05 34.52 2.49–91.86 0.0877
  Wnt11 3.66 0.19–8.91 32.61 0.84–69.97 0.1588
 Up-regulated in MCL-ICs  
  Wnt5a 1.78 0.76–21.93 10.5 3.56–17.87 0.3465
  Wnt3 1.49 0.98–35.36 23.32 4.26–47.61 0.0500
  Wnt8b 1.25 0.39–2.60 3.89 1.45–15.16 0.2308
  Wnt4 1.76 0.21–6.13 3.41 0.54–5.65 0.2820
  Wnt7a 1.21 0.75–5.32 2.09 0.60–6.76 0.2715
  Wnt6 1.02 0.05–17.65 1.85 0.08–8.71 0.5133
  Wnt5b 0.66 0.42–18.82 45.47 0.95–146.30 0.1956
  Wnt1 0.45 0.15–12.25 9.26 4.18–15.20 0.1528
  Wnt7b 0.28 0.25–2.24 4.15 2.13–7.85 0.0156
  Wnt9b 0.39 0.15–1.47 2.44 1.08–8.79 0.1764
  Wnt2b 0.28 0.16–8.18 1.39 0.05–9.60 0.0802
  Wnt10a 0.67 0.24–14.80 0.96 0.03–4.41 0.5622
 Up-regulated in MCL-non-ICs  
  Wnt9a 229.93 4.51–962.28 18.31 10.81–304.06 0.3201
  Wnt16 11.99 1.32–32.97 4.61 3.23–9.86 0.3029
  Wnt8a 6.97 0.24–18.73 1.01 0.15–2.32 0.1785
FZD Receptors      
 Up-regulated in MCL-non-ICs and MCL-ICs  
  Fz2 37.31 4.24–58.26 46.96 10.01–157.60 0.2909
  Fz7 4.53 0.49–9.76 4.48 1.89–9.04 0.9536
 Up-regulated in MCL-ICs  
  Fz4 1.15 0.07–2.52 122.7 1.93–1340 0.3002
  Fz1 1.8 1.10–7.76 25.41 4.65–37.39 0.0390
  Fz5 1.43 0.99–4.45 7.37 3.58–8.77 0.0100
  Fz9 1.44 0.59–2.75 4.74 2.81–8.08 0.0379
  Fz10 0.64 0.29–1.44 4.26 3.91–10.99 0.0738
  Fz8 0.13 0.01–0.39 0.77 0.10–4.76 0.2907
 Up-regulated in MCL-non-ICs  
  Fz6 5.02 4.47–5.59 1.34 0.66–1.85 0.0001
  Fz3 0.3 0.12–7.04 0.26 0.24–1.22 0.4814
  1. B-cells (median = 1) are used as reference. Median with 95 % confidence interval limits depicts the variations observed among patient samples. Differences between MCL-ICs and MCL-non-ICs were considered as significant with P < 0.05.
  2. MCL mantle cell lymphoma, ICs initiating cells